Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 22, 2022 - Issue 4
Submit an article Journal homepage
4,189
Views
2
CrossRef citations to date
0
Altmetric
Review

Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis

Marinos C Dalakasa Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USACorrespondence[email protected]
View further author information
&
Andreas Meiselb Department of Neurology, Integrated Center for Myasthenia Gravis, Charité - University Medicine Berlin, Berlin, GermanyView further author information
Pages 313-318 | Received 14 Sep 2021, Accepted 21 Mar 2022, Published online: 05 Apr 2022

References

  • Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15(2):113–124.
  • Dalakas MC. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. Curr Opin Neurol. 2020;33(5):545–552.
  • Zhu KY, Feferman T, Maiti PK, et al. Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms. J Neuroimmunol. 2006;176(1–2):187–197.
  • Ragheb S, Lisak R, Lewis R, et al. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. Arch Neurol. 2008;65(10):1358–1362.
  • Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021;14:1756286421997381.
  • Basta M, Illa I, Dalakas MC. Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barré syndrome, myasthenia gravis and dermatomyositis. J Neuroimmunol. 1996;71(1–2):227–229.
  • Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994;94(5):1729–1735.
  • Tackenberg B, Jelcic I, Baerenwaldt A, et al. Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A. 2009;106(12):4788–4792.
  • Xu W, Ren M, Ghosh S, et al. Defects of CTLA-4 are associated with regulatory T cells in myasthenia gravis implicated by intravenous immunoglobulin therapy. Mediators Inflamm. 2020;2020:3645157.
  • Su S, Liu Q, Zhang X, et al. VNTR2/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis. Ther Adv Neurol Disord. 2021;14:1756286420986747.
  • Monsul NT, Patwa HS, Knorr AM, et al. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci. 2004;217(2):131–133.
  • Jayam Trouth A, Dabi A, Solieman N, et al. Myasthenia gravis: a review. Autoimmune Dis. 2012;2012:874680.
  • Hehir MK, Silvestri NJ. Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology. Neurol Clin. 2018;36(2):253–260.
  • Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000;70(1):327–334.
  • Oger J, Frykman H. An update on laboratory diagnosis in myasthenia gravis. Clin Chim Acta. 2015;449:43–48.
  • Schroeter M, Thayssen G, Kaise J. Myasthenia gravis – exacerbation and crisis. Neurology International Open. 2018;2(1):E10–E15.
  • Hoffmann S, Kohler S, Ziegler A, et al. Glucocorticoids in myasthenia gravis - if, when, how, and how much? Acta Neurol Scand. 2014;130(4):211–221.
  • Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.
  • Wolfe GI, Kaminski HJ, Aban IB, et al. MGTX Study Group. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511–522.
  • Rückert JC, Swierzy M, Kohler S, et al. Thymectomy in myasthenia gravis. Neurol Int Open. 2018;2(2):E124–E130.
  • Howard JF Jr, Utsugisawa K, Benatar M, et al. REGAIN Study Group. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976–986.
  • Karelis G, Balasa R, De Bleecker JL, et al., A phase 3 multicenter, prospective, open-label efficacy and safety study of immune globulin (human) 10% caprylate/chromatography purified in patients with myasthenia gravis exacerbations. Eur Neurol. 2019; 81(5–6): 223–230.
  • Nowak RJ, Coffey CS, Goldstein JM, et al. NeuroNEXT NN103 BeatMG Study Team. Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized Myasthenia Gravis: the BeatMG Study. Neurology. 2021 Dec 2. Doi:https://doi.org/10.1212/WNL.0000000000013121.
  • FDA News Release. FDA approves new treatment for Myasthenia Gravis. [cited Dec 2021] Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-myasthenia-gravis

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.